Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemoradiation for Recurrent Esophageal Squamous Cell Carcinoma
NCT01402180Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Dec 2010
- Primary completion
- Dec 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01402180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01402180.